Overview

Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers

Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single site, randomized, double masked, comparator-controlled study designed to evaluate the efficacy of lifitegrast ophthalmic solution 5% in treating the symptoms of dry eye in soft contact lens wearers as compared to control. We hypothesize that there will be a significant improvement in dry eye symptoms in contact lens wearers using lifitegrast as compared to those being treated with control (lifitegrast vehicle).
Phase:
Phase 4
Details
Lead Sponsor:
State University of New York College of Optometry
Collaborator:
Novartis Pharmaceuticals
Treatments:
Lifitegrast
Ophthalmic Solutions
Pharmaceutical Solutions